TB-500
Synthetic fragment studied for actin regulation, cell migration, and tissue repair signaling.
Mechanism of Action
Bioregulator compound with targeted biochemical activity.
Evidence Chain
TB-500
COMPOUND
1 Research Goal
• Injury & Wound Healing
Evidence Strength
11 articles sourced
Knowledge Graph
(12 connections)Research Evidence
(11)Ligandrol (LGD-4033): Evidence-Based Research Review
Ligandrol (LGD-4033), also known as VK5211, is a potent, non-steroidal selective androgen receptor modulator (SARM) developed for the treatment of conditions characterized by muscle wasting and osteoporosis. As a SARM, it is designed to exert anabolic effects on skeletal muscle and bone while minimi
Clomiphene Citrate: Evidence-Based Research Review
Clomiphene citrate (CC) is a non-steroidal triphenylethylene derivative classified as a Selective Estrogen Receptor Modulator (SERM). Originally developed for the induction of ovulation in women with anovulatory infertility, it has become a cornerstone of reproductive medicine. CC operates as a race
Tamoxifen Citrate: Evidence-Based Research Review
Tamoxifen citrate is a non-steroidal triphenylethylene derivative and the prototypic Selective Estrogen Receptor Modulator (SERM). Originally developed as a contraceptive, it has become a cornerstone in the treatment and prophylaxis of estrogen receptor-positive (ER+) breast cancer. Tamoxifen exhibi
Oxandrolone: Evidence-Based Research Review
Oxandrolone (17β-hydroxy-17α-methyl-2-oxa-5α-androstan-3-one) is a synthetic oral anabolic-androgenic steroid (AAS) derived from dihydrotestosterone (DHT). Characterized by a unique substitution of an oxygen atom for the carbon at the C-2 position in the A-ring, oxandrolone exhibits a high anabolic-
Nandrolone Decanoate: Evidence-Based Research Review
Nandrolone decanoate (ND) is a long-acting injectable ester of the anabolic-androgenic steroid (AAS) nandrolone (19-nortestosterone). Characterized by a high anabolic-to-androgenic ratio, ND has been utilized clinically for decades to treat conditions involving protein catabolism, bone density loss,
Methenolone Enanthate: Evidence-Based Research Review
Methenolone enanthate is a long-acting injectable anabolic-androgenic steroid (AAS) derived from dihydrotestosterone (DHT). Characterized by a 1-methyl modification and a 2-oxo group, it exhibits a high anabolic-to-androgenic ratio and is notable for its inability to aromatize into estrogen. Origina
BPC-157 and Tissue Repair Signaling Pathways
Comprehensive review of BPC-157 mechanisms in tissue repair, angiogenesis, and mucosal healing.
Thymalin: Thymic Peptide Immunomodulation — Clinical and Translational Evidence
Thymalin is a thymus-derived peptide preparation used clinically in several countries for immunomodulation. This review summarizes the translational and clinical evidence supporting its use in immune restoration.
Andarine (S-4): Evidence-Based Research Review
Andarine (also known as S-4 or GTx-007) is an early-generation, nonsteroidal selective androgen receptor modulator (SARM) belonging to the aryl propionamide class. Developed initially for the treatment of conditions such as muscle wasting and osteoporosis, Andarine demonstrates high affinity for the
Boldenone Undecylenate: Evidence-Based Research Review
Boldenone undecylenate, a synthetic derivative of testosterone originally developed for veterinary use, is a long-acting injectable anabolic-androgenic steroid (AAS). Characterized by a double bond between the C1 and C2 positions, the compound exhibits a favorable ratio of anabolic to androgenic act
Peptide Synergy: Tissue Recovery and Wound Healing
Evidence-based review of wound healing peptide synergy, examining angiogenesis, collagen deposition, and tendon repair mechanisms.
Overview
TB-500 is a synthetic peptide fragment representing a key active sequence of thymosin beta-4 (TMSB4X), a naturally occurring 43-amino-acid protein. The TB-500 peptide (typically 17-23 amino acids in length) captures the actin-binding domain of thymosin beta-4, which is responsible for many of its tissue-repair properties. Originally developed for equine and racing applications, TB-500 has become a prominent subject in tissue repair and regenerative medicine research.
Mechanism of Action
TB-500's primary mechanism involves the sequestration of G-actin monomers, regulating the dynamic polymerization and depolymerization of the actin cytoskeleton — a critical process in cell migration, wound healing, and tissue remodeling. By modulating actin dynamics, TB-500 promotes endothelial cell migration, keratinocyte migration, and fibroblast activity. It also upregulates VEGF expression, promoting angiogenesis in damaged tissue. Additionally, TB-500 demonstrates anti-inflammatory effects through modulation of inflammatory cytokine production and cellular immune responses.
Research Highlights
Animal studies have demonstrated TB-500's efficacy in promoting wound healing, reducing scar tissue formation, and accelerating recovery from muscle, tendon, and ligament injuries. Research has shown cardioprotective effects, with TB-500 reducing damage and improving recovery in models of myocardial infarction. Studies have explored its potential in corneal healing, dermal wound repair, and treatment of chronic inflammatory conditions. TB-500 has been shown to promote cell migration and tissue remodeling in multiple organ systems, with effects observed within days of administration in some models.
Dosage & Administration
In research and veterinary applications, TB-500 has been administered via subcutaneous injection at doses typically ranging from 2-5 mg per week, often divided into multiple administrations. Loading phases of 4-6 weeks followed by maintenance phases have been described in research literature. No standardized human dosing protocols exist. For research use only (RUO).
Safety Profile
Preclinical studies have reported favorable safety profiles, with no significant adverse effects at therapeutic doses. Long-term safety data in humans is absent. As an investigational peptide, contraindications and drug interactions have not been fully characterized. Not approved by the FDA for any indication.
References
Goldstein AL, et al. Thymosin beta4: a novel peptide for tissue repair. Ann N Y Acad Sci. 2010. Philp D, et al. Thymosin beta4 and wound healing. Expert Opin Biol Ther. 2007. Bock-Marquette I, et al. Thymosin beta4 and cardiac repair. Ann N Y Acad Sci. 2007. All content is for educational and research purposes only.
FDA 2026 Regulatory Update
As of April–June 2026, this compound was among the 14 peptides formally removed from the FDA's Category 2 restricted compounding list following review by the Pharmacy Compounding Advisory Committee (PCAC). This regulatory shift permits licensed compounding pharmacies to produce and dispense this compound under appropriate oversight, subject to final 503A Bulks List adjudication expected following the July 23–24, 2026 PCAC meeting. This does not constitute FDA approval for therapeutic use. All information on this page is for research purposes only.
Related Compounds
Synergy & Compatibility
(5)Computational assessment of bio-regulatory compatibility with compounds sharing research goals. Scores reflect half-life alignment, receptor target overlap, and bioavailability data.
Computational assessment based on available pharmacology data. Does not account for individual variability, dose-dependent effects, or unstudied interactions. For research use only.
Community Observations
(0)Qualitative, self-reported researcher observations. Distinct from peer-reviewed evidence — not medical advice.
No approved observations yet. Sign in to contribute.
For research use only. Not medical advice.